Risk factors for fecal carriage of drug-resistant Escherichia coli: a systematic review and meta-analysis.
Adolescent
Adult
Aged
Anti-Bacterial Agents
/ therapeutic use
Carbapenem-Resistant Enterobacteriaceae
/ drug effects
Drug Resistance, Bacterial
/ genetics
Escherichia coli
/ genetics
Escherichia coli Infections
/ epidemiology
Feces
/ microbiology
Feeding Behavior
Genes, Bacterial
Humans
Middle Aged
Prevalence
Risk Factors
Travel
Young Adult
Commensal Escherichia coli
Drug resistance
Meta-analysis
Risk factors
Systematic review
Journal
Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411
Informations de publication
Date de publication:
11 02 2020
11 02 2020
Historique:
received:
15
10
2019
accepted:
30
01
2020
entrez:
13
2
2020
pubmed:
13
2
2020
medline:
30
12
2020
Statut:
epublish
Résumé
Antimicrobial resistance is a serious public health problem. Fecal carriage of drug-resistant bacteria has been suggested as an important source of antimicrobial resistant genes (ARGs). We aimed to identify risk factors associated with fecal carriage of drug-resistant commensal Escherichia coli among healthy adult population. We conducted a systematic review and meta-analysis following the PRISMA guideline. We identified observational studies published from 2014 to 2019 through PubMed, Embase, and Web of Science. Studies were eligible if they investigated and reported risk factors and accompanying measure of associations for fecal carriage of drug-resistant E. coli for healthy population aged 18-65. Data on risk factors assessed in three or more studies were extracted. Fifteen of 395 studies involving 11480 healthy individuals were included. The pooled prevalence of drug-resistant Enterobacteriaceae was 14% (95% confidence interval [CI] 8-23%). Antimicrobial use within the 12 months prior to stool culture (odds ratio [OR] 1.84 [95%CI 1.35-2.51]), diarrhea symptoms (OR 1.56 [95%CI 1.09-2.25]), travel to India (OR 4.15 [95%CI 2.54-6.78]), and vegetarian diet (OR 1.60 [95%CI 1.00(1.0043)-2.56(2.5587)]) were associated with increased risk of fecal carriage of drug-resistant E. coli. Among travellers, antimicrobial use (OR 2.81 [95%CI 1.47-5.36]), diarrhea symptoms (OR 1.65 [95%CI 1.02-2.68]), travel to India (OR 3.80 [95%CI 2.23-6.47]), and vegetarian diet (OR 1.92 [95%CI 1.13-3.26]) were associated with increased risk. Among general adult population, antimicrobial use (OR 1.51 [95%CI 1.17-1.94]), diarrhea symptoms (OR 1.53 [95%CI 1.27-1.84]), and travel to Southeast Asia (OR 1.67 [95%CI 1.02-2.73]) were associated with the increased risk of drug-resistant E. coli carriage. The findings indicate that dietary habit as well as past antimicrobial use and travel to high-risk country are associated with the risk of fecal carriage of drug-resistant commensal E. coli.
Sections du résumé
BACKGROUND
Antimicrobial resistance is a serious public health problem. Fecal carriage of drug-resistant bacteria has been suggested as an important source of antimicrobial resistant genes (ARGs). We aimed to identify risk factors associated with fecal carriage of drug-resistant commensal Escherichia coli among healthy adult population.
METHODS
We conducted a systematic review and meta-analysis following the PRISMA guideline. We identified observational studies published from 2014 to 2019 through PubMed, Embase, and Web of Science. Studies were eligible if they investigated and reported risk factors and accompanying measure of associations for fecal carriage of drug-resistant E. coli for healthy population aged 18-65. Data on risk factors assessed in three or more studies were extracted.
RESULTS
Fifteen of 395 studies involving 11480 healthy individuals were included. The pooled prevalence of drug-resistant Enterobacteriaceae was 14% (95% confidence interval [CI] 8-23%). Antimicrobial use within the 12 months prior to stool culture (odds ratio [OR] 1.84 [95%CI 1.35-2.51]), diarrhea symptoms (OR 1.56 [95%CI 1.09-2.25]), travel to India (OR 4.15 [95%CI 2.54-6.78]), and vegetarian diet (OR 1.60 [95%CI 1.00(1.0043)-2.56(2.5587)]) were associated with increased risk of fecal carriage of drug-resistant E. coli. Among travellers, antimicrobial use (OR 2.81 [95%CI 1.47-5.36]), diarrhea symptoms (OR 1.65 [95%CI 1.02-2.68]), travel to India (OR 3.80 [95%CI 2.23-6.47]), and vegetarian diet (OR 1.92 [95%CI 1.13-3.26]) were associated with increased risk. Among general adult population, antimicrobial use (OR 1.51 [95%CI 1.17-1.94]), diarrhea symptoms (OR 1.53 [95%CI 1.27-1.84]), and travel to Southeast Asia (OR 1.67 [95%CI 1.02-2.73]) were associated with the increased risk of drug-resistant E. coli carriage.
CONCLUSIONS
The findings indicate that dietary habit as well as past antimicrobial use and travel to high-risk country are associated with the risk of fecal carriage of drug-resistant commensal E. coli.
Identifiants
pubmed: 32046786
doi: 10.1186/s13756-020-0691-3
pii: 10.1186/s13756-020-0691-3
pmc: PMC7014593
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
31Références
J Natl Cancer Inst. 1959 Apr;22(4):719-48
pubmed: 13655060
Anim Health Res Rev. 2017 Jun;18(1):46-57
pubmed: 28641596
Int J Environ Res Public Health. 2013 Nov 25;10(12):6235-54
pubmed: 24287850
Lancet Planet Health. 2018 Nov;2(11):e489-e497
pubmed: 30396440
Antimicrob Resist Infect Control. 2012 Nov 27;1(1):39
pubmed: 23181506
BMC Res Notes. 2019 Aug 16;12(1):516
pubmed: 31420003
Pharmacotherapy. 2015 Oct;35(10):949-62
pubmed: 26497481
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Appl Environ Microbiol. 2015 May 1;81(9):3115-20
pubmed: 25724954
J Med Microbiol. 2019 May;68(5):679-692
pubmed: 30990401
BMJ. 2010 May 18;340:c2096
pubmed: 20483949
PLoS One. 2018 Aug 13;13(8):e0200894
pubmed: 30102698
Antimicrob Resist Infect Control. 2019 Jun 10;8:98
pubmed: 31198531
mSphere. 2018 Aug 15;3(4):
pubmed: 30111626
PLoS One. 2015 Jan 14;10(1):e0113033
pubmed: 25587716
Stat Med. 1993 Dec 30;12(24):2273-84
pubmed: 7907813
Emerg Infect Dis. 2011 Oct;17(10):1791-8
pubmed: 22000347
Travel Med Infect Dis. 2015 May-Jun;13(3):223-9
pubmed: 25982453
Clin Infect Dis. 2016 Aug 1;63(3):310-8
pubmed: 27143671
Clin Infect Dis. 2001 Apr 15;32(8):1162-71
pubmed: 11283805
Clin Microbiol Infect. 2017 Feb;23(2):120.e1-120.e8
pubmed: 27773759
Am J Infect Control. 2017 Oct 1;45(10):1101-1105
pubmed: 28629757
Clin Microbiol Rev. 2013 Oct;26(4):744-58
pubmed: 24092853
Infect Control Hosp Epidemiol. 2016 Nov;37(11):1288-1301
pubmed: 27573805
Clin Infect Dis. 2004 Jul 15;39(2):219-26
pubmed: 15307031
BMJ Open. 2019 Mar 5;9(3):e023859
pubmed: 30842108
Ann Clin Microbiol Antimicrob. 2017 Sep 19;16(1):62
pubmed: 28927454
J Travel Med. 2017 Apr 1;24(suppl_1):S29-S34
pubmed: 28520999
J Antimicrob Chemother. 2018 May 1;73(5):1368-1388
pubmed: 29514211
mBio. 2019 Aug 27;10(4):
pubmed: 31455657
mBio. 2017 Jun 27;8(3):
pubmed: 28655818
Methods Mol Biol. 2009;532:397-411
pubmed: 19271198
J Antimicrob Chemother. 2016 Dec;71(12):3548-3555
pubmed: 27566312
J Travel Med. 2016 Feb 08;23(2):tav024
pubmed: 26858272
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
J Appl Microbiol. 2018 Nov;125(5):1228-1237
pubmed: 29957827
Appl Environ Microbiol. 2011 Mar;77(5):1601-7
pubmed: 21216903
BMC Med Res Methodol. 2014 Feb 18;14:25
pubmed: 24548571
Infect Control Hosp Epidemiol. 2016 Jan;37(1):49-54
pubmed: 26458226
Epidemiol Infect. 2017 Jul;145(10):2003-2010
pubmed: 28462735
Braz J Microbiol. 2015 Mar 01;46(1):1-5
pubmed: 26221083
Int J Med Microbiol. 2017 Dec;307(8):497-507
pubmed: 29031453
Environ Res. 2017 May;155:359-364
pubmed: 28273621
Lancet Infect Dis. 2017 Jan;17(1):78-85
pubmed: 27751772
Int J Infect Dis. 2015 Feb;31:31-4
pubmed: 25528484
Clin J Am Soc Nephrol. 2017 Jul 7;12(7):1139-1146
pubmed: 28663227
J Antimicrob Chemother. 2016 Apr;71(4):1076-82
pubmed: 26755493
J Food Prot. 2016 Nov;79(11):1846-1853
pubmed: 28221925
Int J Med Microbiol. 2015 Jan;305(1):148-56
pubmed: 25547265